Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Marissa Chaet Brykman, JD, Virginia Streusand Goldman, PhD, Nandakumara Sarma, PhD, RPh, Hellen A. Oketch-Rabah, PhD, MSc, Deborah Biswas, JD, and Gabriel I. Giancaspro, PhD
Increase in dietary supplement use in the United States suggests a great need for clinicians to be aware of the range of their quality parameters.
AMA J Ethics. 2022;24(5):E382-389. doi:
10.1001/amajethics.2022.382.
Marissa Chaet Brykman joins Ethics Talk to discuss her article, coauthored with Dr Virginia Streusand Goldman, Dr Nandakumara Sarma, Dr Hellen A. Oketch-Rabah, Deborah Biswas and Dr Gabriel I. Giancaspro: “What Should Clinicians Know About Dietary Supplement Quality?”